Entry |
|
Name |
Migaldendranib (USAN/INN) |
Formula |
C853H1464F7N235O237
|
Exact mass |
18925.9618
|
Mol weight |
18937.17
|
Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
|
Efficacy |
Angiogenesis inhibitor (ophtalmologic), Receptor tyrosine kinase inhibitor |
Comment |
Treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME)
Dendrimer
|
Target |
|
Pathway |
|
Interaction |
|
Brite |
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
D13058 Migaldendranib
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
PDGFR family
PDGFRA
D13058 Migaldendranib (USAN/INN)
PDGFRB
D13058 Migaldendranib (USAN/INN)
KIT (CD117)
D13058 Migaldendranib (USAN/INN)
VEGFR family
VEGFR1 (FLT1)
D13058 Migaldendranib (USAN/INN)
VEGFR2 (KDR)
D13058 Migaldendranib (USAN/INN)
Cytokines and receptors
Cytokine receptors
CSF and other factor receptors
CSF1R (FMS, CD115)
D13058 Migaldendranib (USAN/INN)
|
Other DBs |
|
LinkDB |
|